Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Global Blood Therapeutics, Inc. (GBT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
27.33+0.49 (+1.83%)
At close: 04:00PM EDT
27.25 -0.08 (-0.29%)
After hours: 04:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close26.84
Open27.23
Bid24.55 x 1000
Ask29.60 x 800
Day's Range26.04 - 27.50
52 Week Range22.67 - 41.73
Volume1,211,039
Avg. Volume1,193,808
Market Cap1.761B
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-4.45
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.63
  • GlobeNewswire

    GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress

    New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced five abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2022 Hybrid Congress. Presentations include new real-world evidence data on Oxbryta® (voxelotor) as well as an

  • Simply Wall St.

    Shareholders in Global Blood Therapeutics (NASDAQ:GBT) have lost 58%, as stock drops 24% this past week

    If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

  • Motley Fool

    Why Global Blood Therapeutics Stock Was Sickly Today

    For the quarter, Global Blood Therapeutics' sales hit nearly $55.2 million, representing quite an encouraging improvement over the year-ago quarter's $39 million. Although the revenue figure didn't quite reach the $56.1 million analysts were collectively estimating, Global Blood Therapeutics beat on the bottom line. Global Blood Therapeutics also launched the drug for patients aged 4 to 11.

Advertisement
Advertisement